This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study Comparing Radiochemotherapy With Folfox 4 Regimen or 5FU-Cisplatin in Patients With Inoperable Esophageal Cancer

This study has been completed.
Information provided by:
Sanofi Identifier:
First received: September 9, 2005
Last updated: December 4, 2009
Last verified: December 2009

The primary objectives of this study are to assess the feasibility (completion of full treatment) in both arms and to assess endoscopic complete response rate in both arms.

The secondary objective of this study is to assess the toxicity profile of each arm using the National Cancer Institute-Common Toxicity Criteria (NCI-CTC) scale (V.3).

Condition Intervention Phase
Esophageal Neoplasms Drug: FOLFOX 4 Drug: 5-FU / Cisplatin Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Study Comparing Radiochemotherapy With the Folfox 4 Regimen Versus Radiochemotherapy With 5FU-Cisplatin (Herskovic Regimen) in First Line Treatment of Patients With Inoperable Esophageal Cancer

Resource links provided by NLM:

Further study details as provided by Sanofi:

Primary Outcome Measures:
  • Percentage of patients having completed the full treatment and Endoscopic complete response rate [ Time Frame: at the end of the study ]

Secondary Outcome Measures:
  • Toxicity profile (NCI-CTC). [ Time Frame: evaluated each week ]

Enrollment: 97
Study Start Date: September 2004
Primary Completion Date: October 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: FOLFOX 4
total treatment of six 2-weekly cycles of FOLFOX 4, the first 3 cycles starting on D1, D15 and D29 concomitant with 5 weeks' radiotherapy.
Active Comparator: 2 Drug: 5-FU / Cisplatin
two cycles of 5-FU / Cisplatin on week 1 and 5 of radiotherapy and two cycles of chemotherapy with 5-FU / Cisplatin on week 8 and 11 (one cycle each three weeks after the end of radiotherapy).


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Patients with:

  • Histologically proven adenocarcinoma, squamous cell or adenosquamous carcinoma of the esophagus
  • Inoperable esophageal carcinoma (disease status: any T, N0 or N1, M0 or M1a) or surgical contraindication conditions
  • No prior treatment for esophageal cancer (surgery, laser, chemo- or radiotherapy)
  • Oesophageal dilatation is allowed before or during the treatment, but prior esophageal prosthesis is not allowed
  • Peripheral neuropathy <= NCI-CTC grade 1
  • Age >= 18 years
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) <= 2
  • Sufficient (oral or with gastrostomy) calorific intake (> 1000 Kcal/m2/day)
  • Life expectancy >= 3 months
  • Adequate bone marrow reserve, normal renal and liver functions:

    • Neutrophil count >= 1500/mm³
    • Platelet count >= 100,000/mm³
    • Hemoglobin >= 10 g/dl (after transfusion, if necessary)
    • Creatinine levels <= 1.5 x the upper normal limit of institutional values (ULN)
    • Total bilirubin level < 1.5 x ULN
    • ALT/AST < 2.5 x ULN
    • Prothrombin time >= 60%
  • Laboratory values obtained the week preceding study entry
  • Signed informed consent (prior to all study procedures)
  • Start of treatment within 28 days of inclusion.

Exclusion Criteria:

  • Metastatic disease except for third upper or cervical esophagus tumor with regional nodes, or third lower esophagus tumor with celiac nodes (M1a)
  • Multiple carcinomas of the esophagus
  • Small cell or undifferentiated carcinoma of the esophagus
  • Complete dysphagia (grade 4 NCI-CTC); patient with exclusive parenteral nutrition.
  • Weight loss > 20% normal body weight
  • Pregnant or breast-feeding women
  • Fertile patient not using adequate contraception
  • Peripheral sensitive neuropathy with functional impairment
  • Auditory disorders
  • History of prior malignancies (other than cured non melanoma skin cancer, cured cervical carcinoma in situ or stage I or II node negative head and neck cancer cured > 3 years ago)
  • Prior cervical, thoracic and abdominal radiotherapy with field overlapping the proposed oesophageal radiotherapy field
  • Tracheo-oesophageal fistula or invasion of the tracheo-bronchial tree
  • Previous myocardial infarction (inferior or equal to 6 months). Patients with a previous myocardial infarction superior to 6 months, could be included only if: no transient ischemia is shown by thallium myocardial scintigraphy and favourable advice for chemotherapy is obtained from a cardiologist.
  • Other serious illness or medical conditions (such as symptomatic coronary disease, left ventricular failure or uncontrolled infection)
  • Arterial disease stage II to IV according to the Leriche and Fontaine classification
  • Treatment with any other experimental drugs or participation in another clinical trial within 30 days of study screening
  • Concurrent treatment with any other anti-cancer therapy
  • Concurrent treatment with phenytoin and yellow fever vaccine; geographical, social or psychological circumstances preventing regular follow-up.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00160030

Paris, France
Sponsors and Collaborators
Study Director: Marie SEBILLE Sanofi
  More Information

Responsible Party: Medical Affairs Study Director, sanofi-aventis Identifier: NCT00160030     History of Changes
Other Study ID Numbers: L_9326
Study First Received: September 9, 2005
Last Updated: December 4, 2009

Additional relevant MeSH terms:
Esophageal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Head and Neck Neoplasms
Digestive System Diseases
Esophageal Diseases
Gastrointestinal Diseases
Antineoplastic Agents processed this record on August 16, 2017